# David Waterhouse

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-waterhouse/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,172 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 48 |
| i10-index | 114 |
| Last Known Institution | The US Oncology Network |
| OpenAlex ID | https://openalex.org/A5053359739 |
| ORCID iD | https://orcid.org/0000-0001-5589-9939 |
| Works | 295 |

## Researcher papers

- [Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer/)
- [Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA](https://scholariq.org/papers/sensitive-and-specific-multi-cancer-detection-and-localization-using-methylation/)
- [Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-previously-treated-patients-with-advanced-non/)
- [Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/five-year-outcomes-from-the-randomized-phase-iii-trials-checkmate-017-and-057/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-placebo-as-post-nephrectomy-adjuvant-therapy-for-clear-cell/)
- [Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer](https://scholariq.org/papers/randomized-open-label-phase-iii-trial-of-docetaxel-plus-high-dose-calcitriol/)
- [Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153](https://scholariq.org/papers/continuous-versus-1-year-fixed-duration-nivolumab-in-previously-treated-advanced/)
- [Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)](https://scholariq.org/papers/safety-efficacy-and-patient-reported-health-related-quality-of-life-and-symptom/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)

## Researcher university

- [The US Oncology Network](https://scholariq.org/institutions/the-us-oncology-network/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.